Amicogen, a South Korean biotech company specializing in enzyme production and drug development, has partnered with Lysando, an innovative biotech company focused on antimicrobial Artilysin® development, to tackle the growing problem of mastitis in dairy cows caused by multi-resistant bacteria. By combining their expertise, the companies aim to develop a sustainable and effective solution to this critical challenge in agriculture, reducing the economic impact on farmers while improving animal welfare.
Amicogen, a biotech company based in South Korea specializing in industrial enzyme production and drug development, has partnered with Lysando, an innovative biotech company with expertise in developing antimicrobial Artilysin®, to combat the rising issue of mastitis in dairy cows caused by multi-resistant bacteria. Mastitis is a bacterial infection of the udder caused by various, often multi-resistant strains of bacteria, and is rapidly spreading, particularly in Asia. This leads to animal suffering and significant wastage of milk production, causing the global dairy industry about $20-30 billion in annual revenue loss.
The overuse of antibiotics in animal husbandry has been driving a fast increase in multidrug-resistant pathogens, with approximately 70% of all antibiotics produced globally used in agriculture, often as preventative measures, which has accelerated the spread of resistance. In response to this issue, Amicogen and Lysando have partnered to develop an innovative solution to address this pressing issue. By leveraging their combined expertise, the companies aim to generate a treatment that is both effective and sustainable, reducing the economic impact of mastitis on farmers while improving animal welfare.
The joint effort between Amicogen and Lysando represents a significant step towards combatting the rising problem of antibiotic resistance and improving animal health. The companies foresee continuing their research to deliver innovative solutions for critical challenges. The partnership between these two companies highlights the growing importance of joining forces in biotech and the potential for innovation to address challenges, including those in agriculture.
Amicogen is a leader in the development and production of specialty enzymes and proteins for biopharmaceuticals, food, cosmetics, and other industries. Lysando AG is the market leader for antimicrobial proteins, called Artilysin® molecules. They can effectively eliminate problem-causing bacteria without associated high risk of resistance formation and microbial disbalances. Artilysin® constitutes an innovative, proprietary, and environmentally friendly technology with a wide range of applications.
The partnership between Amicogen and Lysando is a positive step towards addressing the rising issue of antibiotic resistance and improving animal health. The joint effort leverages the companies’ expertise to generate a treatment that is both effective and sustainable, reducing the economic impact of mastitis on farmers while improving animal welfare. This partnership highlights the potential of biotech innovation to address critical challenges, not only in healthcare but also in agriculture.
Image provided by Matthias Zomer